» Articles » PMID: 33634433

Latest Advances to Enhance the Therapeutic Potential of Mesenchymal Stromal Cells for the Treatment of Immune-mediated Diseases

Overview
Publisher Springer
Specialty Pharmacology
Date 2021 Feb 26
PMID 33634433
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stromal cells (MSCs) present the capacity to secrete multiple immunomodulatory factors in response to their microenvironment. This property grants them a golden status among the novel alternatives to treat multiple diseases in which there is an unneeded or exaggerated immune response. However, important challenges still make difficult the clinical implementation of MSC-based therapies, being one of the most remarkable the lack of efficacy due to their transient immunomodulatory effects. To overcome this issue and boost the regulatory potential of MSCs, multiple strategies are currently being explored. Some of them consist of ex vivo pre-conditioning MSCs prior to their administration, including exposure to pro-inflammatory cytokines or to low oxygen concentrations. However, currently, alternative strategies that do not require such ex vivo manipulation are gaining special attention. Among them, the recreation of a three dimensional (3D) environment is remarkable. This approach has been reported to not only boost the immunomodulatory potential of MSCs but also increase their in vivo persistence and viability. The present work revises the therapeutic potential of MSCs, highlighting their immunomodulatory activity as a potential treatment for diseases caused by an exacerbated or unnecessary immune response. Moreover, it offers an updated vision of the most widely employed pre-conditioning strategies and 3D systems intended to enhance MSC-mediated immunomodulation, to conclude discussing the major challenges still to overcome in the field.

Citing Articles

Intraosseous Delivery of Mesenchymal Stem Cells for the Treatment of Bone and Hematological Diseases.

Artamonov M, Sokov E Curr Issues Mol Biol. 2024; 46(11):12672-12693.

PMID: 39590346 PMC: 11592824. DOI: 10.3390/cimb46110752.


Regulation of Immune Checkpoint Antigen CD276 (B7-H3) on Human Placenta-Derived Mesenchymal Stromal Cells in GMP-Compliant Cell Culture Media.

Amend B, Buttgereit L, Abruzzese T, Harland N, Abele H, Jakubowski P Int J Mol Sci. 2023; 24(22).

PMID: 38003612 PMC: 10671289. DOI: 10.3390/ijms242216422.


Factors Defining Human Adipose Stem/Stromal Cell Immunomodulation in Vitro.

Mahmoud M, Abdel-Rasheed M, Galal E, R El-Awady R Stem Cell Rev Rep. 2023; 20(1):175-205.

PMID: 37962697 PMC: 10799834. DOI: 10.1007/s12015-023-10654-7.


Immunomodulatory Effects of Mesenchymal Stem Cells on Drug-Induced Acute Kidney Injury.

Han Q, Wang X, Ding X, He J, Cai G, Zhu H Front Immunol. 2021; 12:683003.

PMID: 34149721 PMC: 8213363. DOI: 10.3389/fimmu.2021.683003.

References
1.
Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez R . Mesenchymal stromal cell based therapies for the treatment of immune disorders: recent milestones and future challenges. Expert Opin Drug Deliv. 2020; 17(2):189-200. DOI: 10.1080/17425247.2020.1714587. View

2.
Zhao L, Chen S, Yang P, Cao H, Li L . The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019; 10(1):182. PMC: 6588914. DOI: 10.1186/s13287-019-1287-9. View

3.
Dulamea A . Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. J Med Life. 2015; 8(1):24-7. PMC: 4397514. View

4.
McKinney J, Doan T, Wang L, Deppen J, Reece D, Pucha K . Therapeutic efficacy of intra-articular delivery of encapsulated human mesenchymal stem cells on early stage osteoarthritis. Eur Cell Mater. 2019; 37:42-59. PMC: 7549187. DOI: 10.22203/eCM.v037a04. View

5.
Galipeau J, Sensebe L . Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018; 22(6):824-833. PMC: 6434696. DOI: 10.1016/j.stem.2018.05.004. View